Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Roche Holding AG Basel American Depositary Shares (OP: RHHBY ) 41.50 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 21, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Roche Holding AG Basel American Depositary Shares < Previous 1 2 3 4 5 6 7 8 9 ... 26 27 Next > Biotech Bull Market: 3 Ways To Play It August 20, 2024 Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. Via Talk Markets Topics Economy Exposures Interest Rates IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter August 19, 2024 The company reported a surprise profit in the second quarter, vs. expectations for losses. Via Investor's Business Daily Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years August 18, 2024 Should Novo Nordisk and Eli Lilly investors be worried about Roche? Via The Motley Fool Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market August 16, 2024 Roche missed out on acquiring a potential blockbuster weight-loss drug, now owned by Eli Lilly, in 2018. The drug, orforglipron, is projected to generate up to $14 billion annually by 2032, while... Via Benzinga Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday? August 15, 2024 Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin... Via Benzinga Exposures Product Safety Prediction: This Company Will Disrupt Eli Lilly and Novo Nordisk in the Weight Loss Market (Hint: It's Not Pfizer) August 15, 2024 There are a number of pharmaceutical companies looking to make waves in the weight loss market. Via The Motley Fool Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome August 13, 2024 Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and... Via Benzinga Merck Stops Lung Cancer Study For Keytruda Combo Due To Ineffective Results, Side Effects August 08, 2024 Merck discontinues the Phase 3 KeyVibe-008 trial for the fixed-dose combination of vibostolimab and Keytruda in extensive-stage small cell lung cancer due to futility in overall survival and increased... Via Benzinga Here's Why Eli Lilly Stock Dropped 12% Last Month August 08, 2024 News from a competitor gave investors an unwelcome dose of reality. Via The Motley Fool Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions August 07, 2024 Roche considers divesting Flatiron Health, acquired for $1.9 billion in 2018, highlighting the challenges big pharma faces with start-up investments. Flatiron's data aids Roche's oncology R&D despite... Via Benzinga Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus August 05, 2024 Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy... Via Benzinga Are Eli Lilly and Novo Nordisk Too Expensive For You? Here Are 4 Other Potential Weight Loss Stocks You May Want to Consider Right Now. August 02, 2024 The popularity surrounding weight loss drugs such as Mounjaro and Ozempic has brought Eli Lilly and Novo Nordisk newfound growth. Via The Motley Fool Weight Loss Drug Stocks Just Took a Hit. Should You Buy the Stock That Caused It? July 29, 2024 Roche's latest breakthrough could be a game changer, but it's still too early to say. Via The Motley Fool Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On July 24, 2024 Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management. Via Benzinga Look Out, Eli Lilly and Novo Nordisk: Could Roche Be the Obesity Drug Stock to Really Watch? July 23, 2024 Roche might give Lilly and Novo Nordisk a run for their money -- sometime down the road. Via The Motley Fool Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier July 22, 2024 Pharmaceutical giants like Roche, Eli Lilly, Novo Nordisk, and Pfizer are racing to develop oral weight loss medications. These drugs promise to complement existing injectables, offering new hope in... Via Benzinga This Big Pharma Could Become a Leading Weight-Loss Stock. Should You Buy It? July 22, 2024 This company hasn't made its debut on the weight-loss market yet, but it may. Via The Motley Fool Better Dark Horse Weight Loss Drug Stock: Pfizer vs. Roche July 22, 2024 Neither is a leader right now, but one of them might be on track to change that. Via The Motley Fool Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review July 19, 2024 The Nasdaq tumbled amid chip woes. Via Investor's Business Daily EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' July 18, 2024 Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. Via Benzinga VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday? July 18, 2024 It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels... Via Benzinga Topics Stocks Exposures US Equities New Data for Genentech’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions July 18, 2024 From Genentech Via Business Wire Why Roche Stock Just Popped, but Eli Lilly and Novo Nordisk Dropped July 17, 2024 Roche has a new GLP-1 weight loss drug in the works -- and one very cheap stock. Via The Motley Fool Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study July 17, 2024 From Genentech Via Business Wire Pfizer And Roche Advance On Their Weight Loss Drug Journeys July 17, 2024 After previously discounting a twice-daily version of its weight loss drug due to patients having difficulties tolerating it, Pfizer Inc (NYSE: PFE) moved forward with the once-daily version. On... Via Benzinga Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? July 17, 2024 Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest... Via Benzinga Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study July 17, 2024 Roche reported promising topline results from a Phase 1 trial of CT-996, an oral GLP-1 receptor agonist for type 2 diabetes and obesity. Participants experienced a mean weight loss of 6.1% in four... Via Benzinga Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity July 17, 2024 From Genentech Via Business Wire Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD) July 08, 2024 From Genentech Via Business Wire 3 Small-Cap Stocks With Explosive 2X Growth Potential July 08, 2024 Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 ... 26 27 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.